INVO Fertility, Inc. (IVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
INVO Fertility, Inc. (IVF) trades at $1.36 with AI Score 17/100 (Grade F). INVO Fertility, Inc. operates as a revenue-generating fertility business. The company also focuses on developing clinical-stage assets in oncology and autoimmune diseases. Market cap: $1.89M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for IVF: IVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IVF: 4/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →INVO Fertility, Inc. (IVF) Healthcare & Pipeline Overview
INVO Fertility, Inc. is a revenue-generating fertility business focused on developing clinical-stage assets in oncology and autoimmune diseases. Headquartered in Sarasota, FL, the company operates within the medical devices industry, offering a unique approach to fertility solutions and exploring opportunities in broader healthcare sectors.
What Is the Investment Thesis for IVF?
INVO Fertility presents a unique investment proposition within the fertility and medical device sectors. The company's INVOcell technology offers a potentially disruptive approach to fertility treatment, providing a more accessible and affordable option compared to traditional IVF. With a gross margin of 39.2%, there is potential for profitability as the company scales its operations. Key growth catalysts include expanding the adoption of INVOcell in existing markets and penetrating new geographic regions. However, the company's negative profit margin of -417.0% and a market capitalization of $1.89M indicate significant financial risks and reliance on future funding. The high beta of 2.67 suggests high volatility relative to the market. Success hinges on effective commercialization of INVOcell and progress in its oncology and autoimmune disease assets.
Based on FMP financials and quantitative analysis
IVF Key Highlights
- Gross Margin of 39.2% indicates potential for profitability with increased scale.
- Focus on INVOcell technology offers a potentially disruptive approach to fertility treatment.
- Operations in the fertility sector address a significant and growing market need.
- Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
- Headquartered in Sarasota, FL, with a team of approximately 30 employees.
Who Are IVF's Competitors?
IVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVF's Key Strengths?
- Proprietary INVOcell technology offers a differentiated approach to fertility treatment.
- Focus on affordability and accessibility expands the potential market for fertility services.
- Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
- Established partnerships with fertility clinics and healthcare providers.
What Are IVF's Weaknesses?
- Negative profit margin indicates financial instability.
- Limited market capitalization reflects investor concerns.
- High beta suggests high volatility relative to the market.
- Reliance on future funding to support operations and development.
What Could Drive IVF Stock Higher?
- Regulatory approvals for clinical-stage assets in oncology and autoimmune diseases could drive significant value.
- Expansion of INVOcell adoption in existing and new markets will drive revenue growth.
- Strategic partnerships with pharmaceutical companies and research institutions can accelerate development and commercialization efforts.
What Are the Key Risks for IVF?
- Financial-distress signal — its Altman Z-Score of -6.22 sits in the distress zone (elevated bankruptcy risk).
- Competition from established IVF providers and other fertility technology companies could limit market share.
- Regulatory hurdles and changing healthcare policies could impact the adoption of INVOcell and the development of new therapies.
- Negative profit margin and reliance on future funding pose financial risks.
- Setbacks in clinical trials for oncology and autoimmune disease assets could delay or halt development.
What Are the Growth Opportunities for IVF?
- Expanding INVOcell Adoption: A significant growth opportunity lies in increasing the adoption of INVOcell technology within existing markets. This involves educating potential patients and healthcare providers about the benefits of INVOcell compared to traditional IVF, focusing on its affordability and more natural approach. Success in this area would drive revenue growth and market share. The global fertility services market is projected to reach billions of dollars, providing a substantial addressable market.
- Geographic Expansion: INVO Fertility can pursue growth by expanding its geographic presence, particularly in underserved markets where access to fertility treatment is limited. This could involve establishing partnerships with local clinics and healthcare providers to offer INVOcell as a viable option. Entering new markets requires careful consideration of regulatory requirements and cultural factors. The timeline for geographic expansion depends on securing necessary approvals and establishing operational infrastructure.
- Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate INVO Fertility's growth. These partnerships can provide access to new technologies, funding, and market channels. Collaborations can also enhance the company's research and development efforts in oncology and autoimmune diseases. The success of partnerships depends on aligning strategic goals and establishing mutually beneficial terms.
- Development of Oncology and Autoimmune Assets: INVO Fertility's development of clinical-stage assets in oncology and autoimmune diseases represents a significant growth opportunity. Advancing these assets through clinical trials and securing regulatory approvals could lead to the commercialization of new therapies and generate substantial revenue. This strategy diversifies the company's portfolio and reduces its reliance on the fertility market. The timeline for developing these assets depends on the progress of clinical trials and regulatory review processes.
- Enhancing Marketing and Sales Efforts: Strengthening marketing and sales efforts is crucial for driving awareness and adoption of INVOcell technology. This involves developing targeted marketing campaigns, participating in industry conferences, and building relationships with key opinion leaders. Effective marketing and sales strategies can increase patient referrals and drive revenue growth. The timeline for implementing these strategies depends on allocating sufficient resources and developing a comprehensive marketing plan.
What Opportunities Does IVF Have?
- Expanding INVOcell adoption in existing and new markets.
- Securing regulatory approvals for oncology and autoimmune disease assets.
- Forming strategic partnerships with pharmaceutical companies and research institutions.
- Increasing awareness and adoption of INVOcell through targeted marketing campaigns.
What Threats Does IVF Face?
- Competition from established IVF providers and other fertility technology companies.
- Regulatory hurdles and changing healthcare policies.
- Potential setbacks in clinical trials for oncology and autoimmune disease assets.
- Economic downturns impacting patient affordability and demand for fertility services.
What Are IVF's Competitive Advantages?
- Proprietary INVOcell technology offers a differentiated approach to fertility treatment.
- Focus on affordability and accessibility expands the potential market for fertility services.
- Development of clinical-stage assets in oncology and autoimmune diseases diversifies the company's portfolio.
- Established partnerships with fertility clinics and healthcare providers.
What Does IVF Do?
Founded on January 5, 2007, INVO Fertility, Inc. is dedicated to providing accessible and innovative fertility solutions. The company operates as a revenue-generating fertility business, primarily focusing on its INVOcell technology, an innovative intravaginal culture (IVC) system. INVOcell is designed to offer a more natural and affordable fertility treatment option compared to traditional in-vitro fertilization (IVF). INVO Fertility aims to expand access to fertility care, particularly in underserved markets. Beyond fertility, INVO Fertility is also involved in the development of clinical-stage assets in oncology and autoimmune diseases, diversifying its portfolio within the healthcare sector. The company is headquartered in Sarasota, FL, and manages its operations with a team of approximately 30 employees.
What Products and Services Does IVF Offer?
- Operates as a revenue-generating fertility business.
- Develops and commercializes the INVOcell system for intravaginal culture (IVC).
- Offers a more affordable and natural alternative to traditional IVF.
- Focuses on expanding access to fertility care.
- Develops clinical-stage assets in oncology and autoimmune diseases.
- Seeks to diversify its healthcare portfolio beyond fertility.
How Does IVF Make Money?
- Generates revenue through the sale of INVOcell devices and related products.
- Partners with fertility clinics to offer INVOcell treatment to patients.
- Potentially generates revenue from the commercialization of oncology and autoimmune disease assets.
- May explore licensing agreements or strategic partnerships to expand market reach.
What Industry Does IVF Operate In?
INVO Fertility operates within the medical devices industry, specifically targeting the fertility sector. The fertility market is driven by increasing rates of infertility, advancements in reproductive technologies, and growing awareness of treatment options. Competition includes established IVF providers and other fertility technology companies. INVO Fertility's INVOcell technology aims to differentiate itself by offering a more accessible and affordable alternative to traditional IVF. The company's expansion into oncology and autoimmune diseases positions it within broader and highly competitive pharmaceutical and biotechnology markets.
Who Are IVF's Key Customers?
- Fertility clinics and healthcare providers.
- Patients seeking fertility treatment.
- Potential partners in the pharmaceutical and biotechnology industries.
- Research institutions involved in oncology and autoimmune disease research.
Key Financial Metrics
Return on assets is -46.5%, showing how much profit it generates from its asset base. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching.
INVO Fertility, Inc. (IVF) Valuation Context
Valued at $1.89M, IVF is classified as a micro-cap stock. Relative to its peer group, IVF's quantitative score of 17/100 is below the peer average of 69/100.
Company Profile
INVO Fertility, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Steven Shum. IVF has traded publicly since 2020.
F-Score 4/9Financial Health
INVO Fertility, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.22 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project INVO Fertility, Inc. revenue of about $10.4M for fiscal 2026, with EPS near $-2.90.
Net buyingInsider Activity
The most recent 7 insider filings for INVO Fertility, Inc. break down as 2 sales and 5 purchases. On net that is roughly 227K shares acquired (about $229K) — insiders putting money in tends to read as conviction.
IVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in INVO's growth potential, indicating that those closest to the company believe in its future.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative approaches in fertility treatments.
- Recent partnerships and collaborations have generated excitement, showcasing INVO's commitment to expanding its market reach.
- The growing demand for fertility services has been a hot topic, positioning INVO as a key player in a rapidly expanding industry.
Bear Case
- Some community members express concerns over competition in the fertility space, which could impact INVO's market share.
- There are ongoing regulatory challenges in the healthcare sector that could pose risks to INVO's operational strategies.
- Recent market developments have raised questions about the sustainability of growth in the fertility market, leading to cautious sentiment among investors.
- Some analysts highlight potential cash flow issues, urging caution as the company navigates its expansion plans.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IVF Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 29, 2026
-
Top Midday Gainers
MT Newswires · Jun 26, 2026
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Jun 26, 2026
-
BC-Most Active Stocks
Associated Press · Jun 26, 2026
IVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVF.
Price Targets
Wall Street price target analysis for IVF.
IVF MoonshotScore
What does this score mean?
The MoonshotScore rates IVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Steven Shum
CEO
Steven Shum is the CEO of INVO Fertility, Inc. His background includes experience in managing and growing companies, although specific details of his career history and education are not available in the provided data. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial for driving the adoption of INVOcell technology and advancing the development of oncology and autoimmune disease assets.
Track Record: Under Steven Shum's leadership, INVO Fertility has focused on expanding the commercialization of INVOcell and exploring opportunities in oncology and autoimmune diseases. Key milestones include establishing partnerships with fertility clinics and advancing clinical-stage assets. However, the company's financial performance, as indicated by its negative profit margin, suggests challenges in achieving profitability.
INVO Fertility, Inc. Healthcare Stock: Key Questions Answered
What does INVO Fertility, Inc. do?
INVO Fertility, Inc. operates as a revenue-generating fertility business, primarily focused on its INVOcell technology. INVOcell is an innovative intravaginal culture (IVC) system designed to offer a more natural and affordable fertility treatment option compared to traditional in-vitro fertilization (IVF). The company aims to expand access to fertility care, particularly in underserved markets. In addition to fertility, INVO Fertility is also involved in the development of clinical-stage assets in oncology and autoimmune diseases, diversifying its portfolio within the healthcare sector.
What are the main risks for IVF?
The main risks for INVO Fertility include its negative profit margin of -417.0%, indicating financial instability and reliance on future funding. Competition from established IVF providers and other fertility technology companies could limit market share. Regulatory hurdles and changing healthcare policies could impact the adoption of INVOcell and the development of new therapies. Potential setbacks in clinical trials for oncology and autoimmune disease assets could delay or halt development. The company's high beta of 2.67 suggests high volatility, adding to the investment risk.
What are the key factors to evaluate for IVF?
INVO Fertility, Inc. (IVF) holds an AI score of 17/100 (low). Not financial advice.
How frequently does IVF data refresh on this page?
IVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IVF's recent stock price performance?
INVO Fertility, Inc. (IVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary INVOcell technology offers a differentiated approach to fertility treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVF overvalued or undervalued right now?
Valuing INVO Fertility, Inc. (IVF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IVF?
Before investing in INVO Fertility, Inc. (IVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IVF to a portfolio?
Key strength of INVO Fertility, Inc. (IVF): Proprietary INVOcell technology offers a differentiated approach to fertility treatment. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not reflect the most current performance.
- AI analysis is pending, which may provide additional insights.
- The company's future performance is subject to significant risks and uncertainties.